Free Trial

Deutsche Bank AG Sells 144,467 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

Terns Pharmaceuticals logo with Medical background

Deutsche Bank AG cut its stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 26.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 398,379 shares of the company's stock after selling 144,467 shares during the period. Deutsche Bank AG owned approximately 0.47% of Terns Pharmaceuticals worth $2,207,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Landscape Capital Management L.L.C. bought a new position in Terns Pharmaceuticals during the 4th quarter worth approximately $73,000. Townsquare Capital LLC acquired a new stake in Terns Pharmaceuticals in the fourth quarter worth $76,000. Oxford Asset Management LLP bought a new position in shares of Terns Pharmaceuticals during the fourth quarter worth $86,000. Savant Capital LLC bought a new position in shares of Terns Pharmaceuticals during the fourth quarter worth $89,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Terns Pharmaceuticals by 33.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,010 shares of the company's stock valued at $100,000 after buying an additional 4,475 shares during the period. 98.26% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TERN shares. JMP Securities reissued a "market outperform" rating and set a $20.00 target price on shares of Terns Pharmaceuticals in a research note on Monday, April 21st. BMO Capital Markets reduced their price target on shares of Terns Pharmaceuticals from $26.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Finally, William Blair reissued a "market perform" rating on shares of Terns Pharmaceuticals in a research report on Friday, March 21st. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $15.63.

View Our Latest Research Report on Terns Pharmaceuticals

Terns Pharmaceuticals Stock Performance

Terns Pharmaceuticals stock traded up $0.14 during midday trading on Wednesday, reaching $3.15. The stock had a trading volume of 100,989 shares, compared to its average volume of 1,526,016. Terns Pharmaceuticals, Inc. has a 1-year low of $1.87 and a 1-year high of $11.40. The firm's fifty day simple moving average is $2.80 and its 200-day simple moving average is $4.26. The stock has a market capitalization of $275.11 million, a P/E ratio of -2.65 and a beta of -0.16.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.03. On average, sell-side analysts anticipate that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current fiscal year.

About Terns Pharmaceuticals

(Free Report)

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

Featured Stories

Institutional Ownership by Quarter for Terns Pharmaceuticals (NASDAQ:TERN)

Should You Invest $1,000 in Terns Pharmaceuticals Right Now?

Before you consider Terns Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.

While Terns Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This Unique Robotaxi Play Could Deliver 10X Returns
NVIDIA’s Secret Picks? 3 Stocks Rising With the AI Giant
NVIDIA Earnings Preview: HUGE Stock Move Ahead

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines